Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial
Authors
Keywords
-
Journal
GUT
Volume 64, Issue 2, Pages 303-311
Publisher
BMJ
Online
2014-04-20
DOI
10.1136/gutjnl-2014-307080
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pegylated Interferon-α2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis
- (2013) Chen-Hua Liu et al. ANNALS OF INTERNAL MEDICINE
- Interferon treatment for patients with chronic hepatitis C complicated with chronic renal failure receiving hemodialysis
- (2013) Akira Kojima et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival Advantage of Kidney Transplantation Over Dialysis in Patients With Hepatitis C
- (2013) Atiporn Ingsathit et al. TRANSPLANTATION
- Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients
- (2012) J. Schreiber et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
- (2012) Chen-Hua Liu et al. ANTIVIRAL THERAPY
- 1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977
- (2012) M.T. Cornpropst et al. JOURNAL OF HEPATOLOGY
- Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy
- (2011) P. Deltenre et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
- (2011) Chen-Hua Liu et al. ANTIVIRAL THERAPY
- Long-Term Viral Negativity After Interferon for Chronic Hepatitis C Virus Infection in Hemodialysis
- (2011) C. E. Gordon et al. Clinical Journal of the American Society of Nephrology
- Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients
- (2011) Samir K. Gupta et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pegylated Interferon Alfa‐2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C
- (2010) Chen‐Hua Liu et al. CLINICAL INFECTIOUS DISEASES
- Treatment of hepatitis C virus infection in patients with end-stage renal disease
- (2010) Chen-Hua Liu et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials
- (2010) Fabrizio Fabrizi et al. JOURNAL OF MEDICAL VIROLOGY
- Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials
- (2010) F. Fabrizi et al. JOURNAL OF VIRAL HEPATITIS
- The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C
- (2010) Chen-Hua Liu et al. KIDNEY INTERNATIONAL
- Pegylated interferon -2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy
- (2009) C-H Liu et al. GUT
- Interferon Treatment in Hemodialysis Patients With Chronic Hepatitis C Virus Infection: A Systematic Review of the Literature and Meta-analysis of Treatment Efficacy and Harms
- (2008) Craig E. Gordon et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3
- (2008) Peter Ferenci et al. HEPATOLOGY
- Treatment of chronic hepatitis C in hemodialysis patients
- (2008) Marina Berenguer HEPATOLOGY
- Ribavirin in the treatment of chronic hepatitis C
- (2008) Paul Martin et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Hepatitis C virus and kidney disease
- (2008) Paul Martin et al. JOURNAL OF HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started